29.07.2015 18:32:00
|
Gilead Sciences, Inc. -- Moody's: Gilead's hepatitis-C sales continue strong streak
New York, July 29, 2015 -- Moody's Investors Service commented that sales of Gilead Sciences, Inc.'s hepatitis-C drugs, Sovaldi and Harvoni, continued their strong and impressive streak in 2Q2015. Gilead is rated A3 with a positive rating outlook.